The development of BsAbs, including anti-VEGF/PD-1(L1) and similar constructs, represents a focused effort to improve anti-tumor immune responses, counteract immune evasion mechanisms, and address the limitations of single-agent therapies. The gene discussed is VEGFA; the disease is neoplasm.